Heart failure & cardiomyopathiesSecondary analysis
Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial
- Secondary analysis of the IRONMAN randomised trial
- hypothesis-generating
Authors' conclusion
This hypothesis-generating analysis suggests that anaemia or TSAT < 20% with ferritin > 100 µg/L might identify patients with heart failure who obtain greater benefit from intravenous iron.
Study context
- Population
- Patients with HF, EF ≤ 45%, and serum ferritin < 100 µg/L or transferrin saturation (TSAT) < 20%
- Participants
- 1,137 patients
- Comparison
- IV ferric derisomaltose vs usual care, by baseline iron/anaemia status
- Primary endpoint
- Relationship of baseline anaemia severity, ferritin and TSAT to haemoglobin change, MLwHF score, 6-minute walk distance and clinical events (recurrent HF hospitalization or CV death)
- Follow-up
- 4 months
Primary result
As reported in the abstract
Response to FDI by baseline blood tests
- Haemoglobin rise with ferric derisomaltose (FDI) greater for lower baseline TSAT
- Pinteraction < .0001
- Haemoglobin rise with FDI greater for lower baseline ferritin
- Pinteraction = .028
- Haemoglobin rise with FDI greater for more severe anaemia
- Pinteraction = .014
- Minnesota Living with Heart Failure (MLwHF) score at 4 months somewhat lower (better) with FDI for more anaemic patients (overall)
- Pinteraction = .14
- MLwHF physical score by anaemia
- Pinteraction = .085
- MLwHF emotional score by anaemia
- Pinteraction = .043
Original publication
Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. Eur Heart J. Published 6 March 2024. doi:10.1093/eurheartj/ehae086
Summarised from the published abstract; every number is checked against it